Daewoong Pharmaceutical and Evolus working together to launch Nabota

- Newly appointed president and management of Evolus visited Daewoong HQ and the NABOTA manufacturing facility

David Moatazedi, President of Evolus, one of global partners of Daewoong Pharmaceutical (CEO Sengho Jeon) for Nabota(DWP-450), visited Daewoong’s HQ and the Nabota manufacturing facility on Oct. 4 and 5, just prior to US launch of Nabota to strengthen their partnership.

This visit was to strategize a successful market entry for Nabota, a botulinum toxin developed by Daewoong Pharmaceutical, for in the US early next year. David Moatazedi and member of Evolus and US doctors shared information in Nabota and exchanged ideas with developers and marketers.

Nabota is currently under FDA and EMA inspection for a launch next year in major cities in the US and Europe.

CEO Sengho Jeon said, “Evolus and we are methodically preparing for launch of Nabota and strengthening our partnership for a successful launch of Nabota in major cities around the world.”

#  #  #

[Photo] Daewoong Pharmaceutical’s Sengho Jeon and Evolus’ David Moatazedi met at Daewoong Pharmaceutical HQ on Oct. 4. The two companies discuss strategies and strengthened their partnership for a successful launch of Nabota in US and Europe early next year.